Special delivery: targeted therapy with small RNAs

Harnessing RNA interference using small RNA-based drugs has great potential to develop drugs designed to knock down expression of any disease-causing gene, thereby greatly expanding the universe of possible drug targets. However, delivering small RNAs into specific tissues and cells is still a hurdle. Here, we review recent progress in overcoming systemic, local and cellular barriers to RNA drug delivery, focusing on strategies for targeted uptake.

[1]  Dan Peer,et al.  The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.

[2]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[3]  Mark E. Davis.  The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[4]  S. Bose,et al.  Administration of connexin43 siRNA abolishes secretory pulse synchronization in GnRH clonal cell populations , 2010, Molecular and Cellular Endocrinology.

[5]  S. Esseghir,et al.  A recombinant H1 histone-based system for efficient delivery of nucleic acids. , 2003, Journal of biotechnology.

[6]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[7]  Qi Zhou,et al.  Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. , 2007, Cancer research.

[8]  P. Mu,et al.  Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl‐xL and cisplatin against prostate cancer , 2009, International journal of cancer.

[9]  Dale L. Greiner,et al.  T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice , 2008, Cell.

[10]  M. Hensel,et al.  Small interfering RNA (siRNA) delivery into murine bone marrow-derived macrophages by electroporation. , 2010, Journal of immunological methods.

[11]  H. Mizusawa,et al.  Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  M. Shimaoka,et al.  Conformational regulation of integrin structure and function. , 2002, Annual review of biophysics and biomolecular structure.

[13]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[14]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[15]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[16]  Junji Kato,et al.  Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone , 2008, Nature Biotechnology.

[17]  D. Kestler,et al.  Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression. , 2006, Journal of biomedical science.

[18]  Kevin Kim,et al.  Silencing by small RNAs is linked to endosomal trafficking , 2009, Nature Cell Biology.

[19]  Wei Yan,et al.  Knockdown of survivin gene expression by RNAi induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721. , 2005, World journal of gastroenterology.

[20]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[21]  D. Greiner,et al.  Targeted Delivery of Small Interfering RNA to Human Dendritic Cells To Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production , 2009, Journal of Virology.

[22]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[24]  Yusuke Yamamoto,et al.  RPN2 gene confers docetaxel resistance in breast cancer , 2008, Nature Medicine.

[25]  M. Eccles,et al.  Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells , 2004, FEBS letters.

[26]  P. Jahrling,et al.  Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference , 2006, The Journal of infectious diseases.

[27]  J. Lieberman,et al.  Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. , 2009, Cell host & microbe.

[28]  Darren H. Wakefield,et al.  Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes , 2007, Proceedings of the National Academy of Sciences.

[29]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[30]  Y. Yuzawa,et al.  A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics , 2004, Cancer Research.

[31]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[32]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[33]  A. Tsubouchi,et al.  Localized suppression of RhoA activity by Tyr31/118-phosphorylated paxillin in cell adhesion and migration , 2002, The Journal of cell biology.

[34]  D. Peer,et al.  RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  T. Ochiya,et al.  Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. , 2006, International journal of oncology.

[36]  J. Lieberman,et al.  Sustained Small Interfering RNA-Mediated HumanImmunodeficiency Virus Type 1 Inhibition in PrimaryMacrophages , 2003, Journal of Virology.

[37]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[38]  Liu Wang,et al.  Decreased cofilin1 expression is important for compaction during early mouse embryo development. , 2009, Biochimica et biophysica acta.

[39]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[40]  J. Lieberman,et al.  Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 , 2007, Proceedings of the National Academy of Sciences.

[41]  L. Mei,et al.  Erbin Suppresses the MAP Kinase Pathway* , 2003, The Journal of Biological Chemistry.

[42]  M. Morris,et al.  A non-covalent peptide-based strategy for siRNA delivery. , 2007, Biochemical Society transactions.

[43]  M. Amarzguioui,et al.  Approaches for chemically synthesized siRNA and vector‐mediated RNAi , 2005, FEBS letters.

[44]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[45]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[46]  A. Sood,et al.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.

[47]  Min Zhang,et al.  Downregulation Enhanced Green Fluorescence Protein Gene Expression by RNA Interference in Mammalian Cells , 2004, RNA biology.

[48]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[49]  Daniel G. Anderson,et al.  Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters). , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  Daniel G. Anderson,et al.  Structure/property studies of polymeric gene delivery using a library of poly(β-amino esters). , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Matthias John,et al.  Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. , 2004, Bioorganic & medicinal chemistry letters.

[52]  John J. Rossi,et al.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells , 2009, Nucleic acids research.

[53]  R. Green,et al.  “I know what you told me, but this is what I think:” Perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate , 2010, Genetics in Medicine.

[54]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[55]  H. Mizusawa,et al.  Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[57]  T. Kubo,et al.  MDR1a/1b gene silencing enhances drug sensitivity in rat fibroblast‐like synoviocytes , 2009, The journal of gene medicine.

[58]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[59]  Jun Wang,et al.  Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis , 2012, Science Translational Medicine.

[60]  B. Williams,et al.  RNA interference in biology and disease. , 2005, Blood.

[61]  N. Kosaka,et al.  Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. , 2004, Nucleic acids research.

[62]  O. Donzé,et al.  RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. , 2002, Nucleic acids research.

[63]  J. Lieberman,et al.  An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection , 2006, Nature.

[64]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[65]  A. Gosain,et al.  TGF-&bgr;1 RNA Interference in Mouse Primary Dura Cell Culture: Downstream Effects on TGF Receptors, FGF-2, and FGF-R1 mRNA Levels , 2009, Plastic and reconstructive surgery.

[66]  A. Judge,et al.  Misinterpreting the therapeutic effects of siRNA caused by immune stimulation , 2008 .